FATE250117C00002000 Option on Fate Therapeutics

FATE Stock  USD 1.27  0.02  1.60%   

Fate Therapeutics Market Cap Over Time

   Market Cap   
       Timeline  

Fate Total Stockholder Equity

Total Stockholder Equity

444.86 Million

At present, Fate Therapeutics' Total Stockholder Equity is projected to increase significantly based on the last few years of reporting.

Fate Therapeutics Corporate Management

Barbara HickingbottomSenior DevelopmentProfile
Andrew HenrySenior OperationsProfile
YuWaye MDChief OfficerProfile
Cindy TahlGeneral SecretaryProfile
Edward IIIChief OfficerProfile
Bahram ValamehrChief Development OfficerProfile
When determining whether Fate Therapeutics is a strong investment it is important to analyze Fate Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Fate Therapeutics' future performance. For an informed investment choice regarding Fate Stock, refer to the following important reports:
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Fate Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate.
For information on how to trade Fate Stock refer to our How to Trade Fate Stock guide.
You can also try the Money Managers module to screen money managers from public funds and ETFs managed around the world.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Fate Therapeutics. If investors know Fate will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Fate Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.64)
Revenue Per Share
0.123
Quarterly Revenue Growth
0.581
Return On Assets
(0.22)
Return On Equity
(0.47)
The market value of Fate Therapeutics is measured differently than its book value, which is the value of Fate that is recorded on the company's balance sheet. Investors also form their own opinion of Fate Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Fate Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Fate Therapeutics' market value can be influenced by many factors that don't directly affect Fate Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Fate Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Fate Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Fate Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.